Punjab, April 28 -- MUMBAI, India, April 28, 2026 /PRNewswire/ - Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Fourth Quarter (Q4) and Full-year ended 31st March 2026. Consolidated Financial Highlights(in Rs. Crores or as stated)ParticularsQ4FY26Q4FY25YoY %FY26FY25YoY %Revenue from Operations2,7522,754(0)%8,8699,151(3)% CDMO1,7081,788(4)%4,9155,447(10)% CHG7557057%2,7032,6333% PCH32027417%1,2741,09317%EBITDA507603(16)%1,1351,580(28)%EBITDA Margin 18%22%13%17%PAT Before Expectational Item1671549%(130)91NMExceptional Item1(176)-NM(196)-NMPAT After Expectational Item(9)154NM(326)91NM1. During the quarter, the m...